Need some inspiration for stocks to buy right now? Here are my top 10 buys -- in no particular order -- for 2025 and beyond.

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.16% higher to $397.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.09% ...

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

Desktop Metal, Inc. ("Desktop Metal") today announced that it has filed a lawsuit against Nano Dimension Ltd. ("Nano Dimension") in the Delaware Court of Chancery (the "Court"), alleging that Nano ...

这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...